drugset / Trial / NCT01740869

Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders

NCT01740869

Phase 3 Completed 30 enrolled Hospital Universitario Dr. Jose E. Gonzalez
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether the plasticity of autologous intrathecal hematopoietic cells would improve the neurologic and the social skills of pediatric patients with autism spectrum disorders.

Timeline

Start
2012-11
Primary completion
2016-11
Completion
2017-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CD34+ hematopoietic stem cells Unknown 5 ml Intrathecal
Subject CD34+ hematopoietic stem cells Unknown 10 ml Intrathecal
Background Granulocyte colony-stimulating factor Protein / enzyme biologic

Indications